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There has been rapid advance in the understanding of aberrant cell
growth in tumours in recent years and this has yielded a number
of potential therapeutic targets for drug development. Second
messenger signal transduction has been of particular interest.
One signalling lipid that is aberrantly regulated in neoplasia is
phosphatidic acid (PA). Cellular levels of PA are increased
following neoplastic transformation with ras and fps oncogenes
(Martin et al, 1991) and elevated levels of PA are correlated with
expression of the src oncogene (Song et al, 1991; Song and Foster,
1993) and the MDR phenotype in tumour cells. PA is involved in
calcium mobilization (Siddiqui and English, 1997), transport from
the endoplasmic reticulum to the Golgi complex (Bi et al, 1997)
and activation of other signalling cascades (Siddiqui and Yang,
1995; English et al, 1996). PA has been linked to the activation of
the neutrophil respiratory burst enzyme, NADPH oxidase (Waite
et al, 1997), and is also a potent mitogen, and may exert its effects
through the action of the small G-proteins (Exton, 1997). The
potential therapeutic index for PA modulators is high, as normal
cells under homeostatic conditions have very low levels of PA,
malignant transformed cells express high levels of PA. 
CT-2584 HMS, 1-(11-dodecylamino-10-hydroxyundecyl)-3,7-
dimethylxanthine-hydrogen methanesulphonate, is a cytotoxic
agent which modulates intracellular metabolism of phosphatidic
acid in tumour cells (Singer et al, 1994; Eiseman et al, 1995). CT-
2584 HMS demonstrated activity against a wide range of human
tumour cells in vitro; lung, colon, melanoma, renal, ovarian,
breast, brain, prostate and leukaemia. National Cancer Institute
(NCI) toxicity testing using the NCI’s preclinical antitumour drug
discovery screen on cell lines derived from 9 human tumours gave
a mean LC50 of 6.14 ± 1.70 µ M. The mean concentration of CT-
2584 HMS that produced growth inhibition of 50% cells (GI50)
was 1.68 ± 0.76 µ M and a mean concentration of CT-2584 HMS
that produced total growth inhibition (TGI) was 3.20 ± 0.64 µ M.
CT-2584 HMS was cytotoxic to cell lines resistant to commonly
used cytotoxic drugs; cisplatin, adriamycin and paclitaxol. With
overnight exposure to CT-2584 HMS the mean LC50 value of
human tumour cell lines resistant to conventional chemothera-
peutic agents was 4.41 ± 3.78 µ M (median 3.29 µ M, range
1.33–11.57  µ M) (data on file, Cell Therapeutics Inc, Seattle,
USA). In contrast, CT-2584 HMS is relatively non-toxic to
haemopoietic cells with a mean LC50 value of 16.26 µ M (range
7.73–39.38 µ M). 
CT-2584 HMS shows antitumour activity in mice with estab-
lished subcutaneous B16 melanoma and established Lewis lung
carcinoma pulmonary metastases. In direct comparisons to
etoposide at its MTD, CT-2584 HMS was as, or more, effective at
suppressing the growth of B16 melanoma and NCI H460 human
lung cancer xenographs. 
The effect of CT-2584 HMS on the growth of a variety of
tumour cells taken directly from patients was tested in a human
tumour soft agar cloning assay. 24-hour exposure to CT-2584
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65% of tumour cells, respectively. 
Preclinical studies were carried out in rats, beagles and non-
human primates. In Sprague Dawley rats, red urine was observed
at doses of 150 mg/m2 and above and was associated with a fall in
haemoglobin and a rise in bilirubin, consistent with intravascular
haemolysis. The LC50 in rats of CT-2584 HMS delivered as a
single 6-hour infusion through the jugular vein was between 650
and 1000 mg/m2. Similar toxicities were seen in Beagles treated at
200, 400 and 800 mg/m2 day–1 × 5 days. In addition, the dogs
exhibited a robust hypersensitivity reaction to Cremophor®EL
and were therefore pre-medicated with Benadryl® 1 hour prior to
dosing with CT-2584 HMS. Non-human primates treated at
1500 mg/m2 over 6 hours a day for 5 consecutive days became
hypotensive, lethargic and developed haematuria and emesis. The
animals recovered several hours after the treatment was discon-
tinued. Doses of 200 mg/m2 day–1 did not result in biologically
significant clinical observations. 
CT-2584 HMS was selected for development on the basis of its
broad antitumour activity and its favourable therapeutic ratio in
tumour cells compared to normal cells. Relatively prolonged
exposure to CT-2584 HMS was associated with increased in vitro
cytotoxicity. The primary objectives of the study were to deter-
mine the maximum tolerated dose (MTD) and safety profile of CT-
2584 HMS and to determine the pharmacokinetic profile of
CT-2584 HMS at escalating dose levels. The secondary objective
was to evaluate the antitumour effects of CT-2584 HMS.
Preclinical toxicity studies showed an LD10 in rats of 650 mg/m2
and a ‘no effect level’ in monkeys (Macaca fascicularis) of
200 mg/m2. 
The target therapeutic dose of CT-2584 HMS is one that would
generate a blood level of 3–5 µ M over a 4 to 6 hour infusion
period. This level and duration are based on in vitro cell cytotoxi-
city data. Stable plasma levels of 0.50 µ M were achieved with a
24-hour infusion of 490 mg/m2 and plasma levels of 2.27 µ M were
achieved with 350 mg/m2 over 3 hours for 3 consecutive days in
non-human primates. 
A Phase I trial using CT-2584 HMS administered intravenously
via a central venous catheter for 6 hours daily for 5 consecutive
days repeated every 3 weeks was designed to study the pharmaco-
logic profile and determine the dose-limiting toxicity in adult
patients with solid malignancies. Based on the LD10 in rats of
650 mg/m2 and the ‘no effect level’ in non-human primates of
200 mg/m2 an initial starting dose of 65 mg/m2 was proposed. This
starting dose was chosen to allow a reasonable margin of safety
with the goal of exceeding the proposed therapeutic blood level
within the dose escalation scheme proposed. 
PATIENTS AND METHODS 
Patient selection 
Patients over 18 years of age with a histologically proven cancer
refractory to conventional therapy or for which no standard
therapy existed were eligible for the trial. Other eligibility criteria
were: Karnofsky score of > 70; expected survival ≥ 12 weeks; no
previous anticancer therapy for 4 weeks (6 weeks for nitrosourea
or mitomycin C); creatinine ≤ 130 µ mol l–1: total bilirubin ≤ 20
µ mol l–1; serum AST and ALT <2 × upper limit of normal range;
WBC ≥ 3.0 × 109 l–1; platelet ≥ 100 × 109 l–1, haemoglobin ≥ 10.0 g
dl–1 and absolute neutrophil count of >1.0 × 109 l–1. Patients with
major thoracic or abdominal surgery within 4 weeks prior to study
drug, cerebral metastases or a history of seizures, hepatitis B or C,
or patients receiving anticoagulants were excluded from the study.
All women of childbearing age were required to have a negative
pregnancy test and to use adequate contraception. The structural
similarity between CT-2584 HMS and methylxanthines suggested
that CT-2584 HMS might have methylxanthine-like side effects
such as angina, hypotension and arrhythmias. A preliminary
preclinical pharmacological profile confirmed CT-2584 HMS to
exhibit mild anti-hypertensive and anti-arrhythmic properties. For
this reason patients with significant cardiovascular disorders, or
patients taking concurrent digoxin therapy were excluded from the
study. Experimental drugs within 28 days prior to dosing were not
permitted. Patients had recovered from all side effects of prior
treatment. Informed written consent was required, and the place-
ment of central venous access for CT-2584 HMS administration.
The protocol was approved by the South Manchester Research
Ethics Committee, and conducted under the auspices of the CRC
Phase I/II Committee. The trial was conducted to the requirements
of Good Clinical Practice Guidelines. 
Treatment and dose escalation 
CT-2584 HMS was manufactured by Sanofi Winthrop, Kansas,
USA and supplied by BlisTech Corporation, Fairfield, New
Jersey, USA for Cell Therapeutics Inc, Seattle, Washington,
USA. 
CT-2584 HMS injection was provided as a sterile solution of
CT-2584 HMS in water for injection at a concentration of
20 mg ml–1. The drug was formulated in Cremophor® EL at a
concentration of 10% v/v. The solution was diluted in 5% dextrose
to a concentration of 2 mg ml– 1 prior to administration, the solu-
tion being stable at room temperature for 24 hours. CT-2584 HMS
is a marked venous irritant (pH 3.75) and the infusion was admin-
istered as a continuous infusion through a tunnelled central venous
catheter. This was placed in the subclavian vein several days prior
to commencing therapy on trial. 
CT-2584 HMS at a starting dose of 65 mg/m2 was given for 6
hours daily for 5 days. Each daily treatment was commenced in the
morning, beginning on day 1. A three-week cycle of CT-2584
HMS consisted of 5 days of CT-2584 HMS administration (Day
1–Day 5). Patients were monitored during each infusion and then
weekly. No intra-patient dose escalations were permitted and the
protocol did not allow dose modifications for individual patients.
A minimum of three patients were treated at each dose level. If one
of the three patients developed a dose limiting toxicity (DLT),
three additional patients were treated at that dose level. Dose
escalation was based on a modified Fibonacci Search Scheme.
Dose limiting toxicity was defined as grade 4 thrombocytopenia
and/or neutropenia or grade 3 non-haematologic toxicity excluding
nausea, vomiting and alopecia. Dose levels of 65 mg/m2, 130 mg/m2,
215 mg/m2, 325 mg/m2, 455 mg/m2 and 585 mg/m2 per day were
defined. Following completion of the 455 mg/m2 dose level and
review of the toxicology, a dose level of 520 mg/m2 was added. 
The maximum tolerated dose (MTD) was defined as the highest
dose at which less than 2 of 6 patients developed a DLT. No patient
was admitted at a higher dose level until all patients at a given
level had reached day 22 of the first cycle. 
For the purposes of the study, an evaluable patient was defined
as one who met all the inclusion criteria and had no exclusion
criteria, and who received at least one dose of CT-2584 HMS. 
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Before initiating therapy, a complete medical history was taken,
documenting all previous surgery, chemotherapy, radiotherapy and
immunotherapy. A physical examination was conducted, baseline
signs and symptoms recorded and determination of Karnofsky
score were recorded within one week prior to commencing therapy
with CT-2584 HMS. All patients had appropriate baseline imaging
and all measurable, evaluable and non-measurable tumour sites
were documented within 4 weeks prior to dosing. A full blood
count (FBC), including differential white cell count, biochemical
screen, coagulation studies (prothrombin time and partial
prothrombin time), hepatitis B and C serology, urinalysis, electro-
cardiogram (ECG) and chest X-ray were performed in all patients
prior to commencing therapy. A pregnancy test was performed in
women with childbearing potential. During the treatment week,
patients had daily complete physical examination and documenta-
tion of Karnofsky score, FBC, biochemistry, urinalysis pre- and
post-infusion and assessment of toxicity. Coagulation studies were
obtained on day 1 and day 5. Toxicity was defined using the
National Cancer Institute of Canada Clinical Trials Group (NCIC-
CTG) Expanded Common Toxicity Criteria (CTC – version 1.0).
An ECG was obtained before each CT-2584 HMS administration.
Tumour evaluation was performed after every two cycles of CT-
2584 HMS. Tumour marker levels were assessed after every
second cycle of CT-2584 HMS in patients who exhibited elevated
levels during the pre-treatment period. Patients with stable disease
or better could receive up to 6 cycles of study treatment. 
Sample collection and drug analysis 
Blood samples for assessment of CT-2584 HMS concentrations
were collected on cycle 1, days 1 and 5. Sample times were imme-
diately prior to commencing the infusion, 1.5 and 5.5 h into the
infusion and immediately at the completion of infusion, 15, 30, 60
min and 2, 4, 6, 12 and 18 h after the completion of the 6-hour
infusion. A 72-h sample was also taken after the completion of
therapy on day 5. Samples (~4.5 ml) were taken into tubes
containing sodium citrate and placed on ice. Each sample was then
centrifuged at 3000 rpm for 20 minutes and the supernatant
removed and frozen at –20˚C prior to analysis. CT-2584 HMS
content was determined by the Bioanalytical Chemistry
Department of Covance Laboratories Inc, Wisconsin using an
HPLC method with ultra-violet (UV) detection. A validation
system was developed ‘in house’ and duplicate samples analysed
(Khan et al, 1999). CT-2584 HMS was extracted into potassium
phosphate extraction buffer and methyl-t-butyl ether from human
plasma. The organic layer was transferred to a clean test tube and
brought to dryness before reconstitution with acetonitrile:sodium
chloroacetate buffer and analysed by HPLC with UV detection.
The peak height ratio of CT-2584 HMS relative to the peak height
of internal standard was determined and a weighted least squares
linear regression analysis was performed. The calibration curve
was then used to calculate the concentration of CT-2584 HMS in
the patient and QC samples. The lower limit of quantitation for
CT-2584 HMS was 20 ng ml–1. Samples from 4 patients were
thawed during shipment, and in 2 patients, high internal standard
responses were obtained which resulted in analysis failure. Results
from the final 2 patients await analysis. 
In 5 patients, multiphasic curves were obtained with CT-2584
HMS and this precluded non-compartmental analysis. A complete
pharmacokinetic profile (Cmax, AUC, T1/2, Vd and CL) was deter-
mined for each evaluable patient using a non-compartmental
model and WinNonlin Professional 2.1 software (Pharsight
Corporation, Cary, NC, USA). 
RESULTS 
A total of 30 patients were enrolled into the study, 13 males and 17
females. 28 patients had a Karnofsky score of 80 to 90, 1 patient
each had scores of 100 and 70. Patients had a wide range of malig-
nancies, and as expected, most patients had received several prior
modalities of treatment. 7 patients had not received prior chemo-
therapy or radiotherapy and all but one of these had advanced
inoperable mesothelioma. Patient characteristics are summarized
in Table 1. 
The safety of CT-2584 HMS was examined at 7 dose levels
from 65 mg/m2 × 5 days to 585 mg/m2 × 5 days. Preclinical toxi-
city studies suggested that CT-2584 HMS could cause anorexia,
decreased activity, haemolysis (presenting with reddening of the
urine) and hypersensitivity reactions and at high doses, vomiting
and convulsions. Catheter-related complications were common. In
the Phase I trial, toxicity was uncommon below 325 mg/m2 × 5
days. At 455 mg/m2 × 5 days, 1 patient experienced grade 3 nausea
and grade 2 vomiting. Grade 2 anorexia was noted in 1 patient.
Cardiovascular side effects were also seen at this dose level with 2
patients developing hypotension and one patient cardiac ischaemia
related to the study drug, drug-related malaise was noted in 5 of 6
patients and this was grade 2 or less. No further drug-related
cardiac toxicity was noted at higher dose levels. At a dose of
520 mg/m2 × 5 days, malaise became more marked, with 4 out of 6
patients developing grade 2 or 3 toxicity. At 585 mg/m2 × 5 days,
grade 3 malaise and grade 4 vomiting was seen in 1 patient. At this
dose, two of three patients discontinued treatment because of drug-
related toxicity and continuation of the study was deemed inappro-
priate. Drug-related toxicities are described in more detail below
and summarized in Table 2. 
Gastrointestinal toxicity 
20 patients (66%) experienced nausea and 16 (53%) experienced
vomiting. Routine prophylactic antiemetics were not given with
the first cycle but when nausea was encountered this was easily
controlled using standard antiemetics (metoclopramide or
ondansetron). 14 patients suffered grade 1 or 2 vomiting, one
patient, treated at 585 mg/m2, developed grade 4 vomiting accom-
panied by grade 3 malaise, facial flushing and backache after
receiving 1100 mg of day 1, cycle 2 dose of CT-2584 HMS
(585 mg/m2). The study drug was discontinued and the symptoms
resolved over the following 3 days. 
Renal and bladder toxicity 
Preclinical animal studies had shown that CT-2584 HMS therapy
could cause red cell haemolysis. Urine was tested for blood,
bilirubin and protein pre- and post-infusion daily during the drug
infusion days. Transient proteinuria was detected in 14 patients
(47%) and haematuria in 10 (33%) patients. Except in two
instances, haematuria was detected only on urinalysis. Macro-
scopic haematuria was observed in two patients. One patient with
an ovarian teratoma treated at a dose level of 520 mg/m2 developed
Phase I trial of CT-2584 HMS 1601
British Journal of Cancer (2000) 83(12), 1599–1606 © 2000 Cancer Research Campaigntransient macroscopic haematuria which was thought to be due to
CT-2584 HMS administration. 
A further patient with ovarian carcinoma and bladder infiltra-
tion developed transient grade 4 haematuria and grade 2 rise in
serum creatinine which was thought to be due to tumour. There
were no treatment modifications or discontinuations related to these
events. 
Hepatic toxicity 
One patient with hepatic serosal involvement from ovarian carci-
noma, had mild elevation in alkaline phosphatase (200 IU l–1,
normal range 25–100 IU l–1) which rose to 416 by day 8 of cycle 1,
and 819 by day 15 before returning to 254 by day 30. Early tumour
progression was evident at day 22. A possible relationship to study
drug was made. 
In two patients, a transient rise in bilirubin was seen. In one
patient, treated at 65 mg/m2, on days 2–4 the maximum total
bilirubin level was 28 µ mol l–1. This patient had also received a
blood transfusion following day 1 CT-2584 HMS administration. 
A further patient was noted to have a raised bilirubin of 23 µ mol
l–1 (normal range 1–20 µ mol l–1) on day 5 of treatment at 455
mg/m2. No clinically significant haemolytic effects or hepatic
adverse events were observed in this trial. 
Haematological toxicity 
CT-2584 HMS did not cause significant myelosuppression. Mild
(grade 1 and 2) anaemia was common, and is likely to be due to
several contributory factors; advanced cancer, compromised bone
marrow function from previous therapy and frequency of blood
sampling during the study. Evidence of direct haemolytic action of
CT-2548 HMS has been demonstrated preclinically and minor
haematuria/haemoglobinuria were observed during urinary mon-
itoring. A small direct contribution to anaemia from CT-2584
HMS cannot be excluded. 
No CT-2584 HMS related changes in white cell or platelet count
were noted during this study. No significant alterations in tests of
coagulation (PT/PPT) were noted. 
Cardiac toxicity 
Three patients treated with CT-2584 HMS developed cardiac side
effects. One patient had incomplete left bundle branch block
(LBBB) on pre-treatment ECG. At completion of day 3 infusion of
cycle 1 at 455 mg/m2, he developed chest pain associated with
sweating and grade 3 hypotension. A repeat ECG revealed
complete LBBB. The patient received intravenous fluids and anal-
gesia and his blood pressure returned to baseline levels. His ECG
had returned to baseline by the following morning. Cardiac
enzymes were checked and were normal. CT-2584 HMS treatment
was discontinued. 
Three weeks after treatment at 325 mg/m2, patient #14 devel-
oped an infected leg ulcer which led to septicaemia. The patient
developed atrial fibrillation associated with this event which was
deemed unrelated to study drug treatment. 
One patient treated at 455 mg/m2, developed anginal chest pain
associated with sweating and vomiting towards the end of day 5,
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Table 1 Patient details 
Pt. no. Age/sex Disease No. cycles  Dose mg/m2 Response Reason stopped
completed
1 33/M Malignant melanoma 2 65 PD HSR 
2 60/M Malignant pleural mesothelioma 6 65  PR Study completed 
3 34/F Metastatic malignant paraganglioma 2 65 PD Disease progression 
4 78/F Malignant melanoma 1 130 PD Disease progression 
5 46/F Ovarian adenocarcinoma 1 130 PD  Disease progression 
6 46/M Non small cell lung carcinoma (adeno) 2  130 PD Disease progression 
7 61/M Malignant pleural mesothelioma 2 130  PD Disease progression 
8 64/F Malignant pleural mesothelioma 4 130  SD Disease progression 
9 41/M Peritoneal mesothelioma 4 130 NE  Patient request, subclavian line malfunction 
10 45/F Ovarian adenocarcinoma 2 215 PD  Disease progression 
11 64/F Ovarian adenocarcinoma 2 215 PD  Disease progression 
12 66/F Unknown primary site carcinoma 2 215  PD Disease progression 
13 46/F Breast carcinoma 2 325 PD Disease progression 
14 67/F Malignant pleural mesothelioma 3 325  SD Sepsis and atrial fibrillation 
15 62/M Malignant pleural mesothelioma 2 325  PD Disease progression 
16 58/M Malignant pleural mesothelioma 1 455  NE Chest pain, hypotension 
17 49/M Malignant pleural mesothelioma 1 455  PD Patient death 
18 49/F Ovarian adenocarcinoma 4 455 SD  Chest pain, ECG changes 
19 45/F Ovarian cystadenocarcinoma 1 455 PD Uncontrolled line sepsis 
20 30/M Osteosarcoma 2 455 PD Disease progression 
21 47/F Inflammatory breast carcinoma 1 455  PD Disease progression 
22 50/M Malignant pleural mesothelioma 1 520  NE Drug toxicity (malaise) 
23 45/F Colonic adenocarcinoma 1 520 NE  Subclavian vein thrombosis 
24 54/F Ovarian carcinoma 2 520 PD Disease progression 
25 28/F Malignant ovarian teratoma 6 520 SD Study completed 
26 45/M Hypernephroma 2 520 SD Patient request 
27 71/M Pulmonary blastoma 4 520 SD Drug toxicity (malaise+nausea) 
28 47/M Gastric adenocarcinoma 3 585 SD  Drug toxicity (malaise) 
29 60/F Hypernephroma 2 585 PD Progressive disease 
30 53/F Soft tissue sarcoma 2 585 PD Drug toxicity (malaise, flushing, headache) 
NE = Not evaluable; SD = Stable disease; PR = Partial response; PD = Progressive disease. cycle 4. There were no ECG changes evident during this episode
but widespread T wave inversion in V2–6 and in leads I and II
developed after 36 hours. The pain responded quickly to analgesia
and discontinuation of the infusion. Chest X-ray and cardiac
enzymes were normal. The patient had no prior cardiac history and
suffered no further cardiac sequelae. These events were judged to
be related to the study drug. 
Malaise 
28 of the 30 patients (93%) experienced malaise, and in a majority
of instances (73%) these were attributed to the study drug. Malaise
typically lasted for a few days after completion of each cycle. This
was reported more frequently at dose levels of 455 mg/m2 and
above. Two of 3 patients at 585 mg/m2 and 4 of 6 patients at
520 mg/m2 developed grade 2 or worse drug-related malaise.
Patient 22 developed grade 3 malaise and nausea one week after
completing the first cycle of CT-2584 HMS. These symptoms had
improved to grade 1 at D21 review. The patient declined further
trial drug treatment. Patients 24, 27 and 28 reported grade 1
malaise at baseline which progressed to grade 2 after cycle 2 in
patient 24 and cycle 3 in patients 27 and 28. In patient 27 this was
associated with grade 3 nausea which required intravenous fluid
replacement and antiemetics. The patient discontinued treatment. 
Patient 30 developed grade 3 malaise, flushing, backache and
vomiting towards the completion of D1, cycle 2 infusion. The
symptoms resolved over the following 24 hours and the study drug
discontinued. Significant malaise was uncommon during the first
week of study drug treatment. In 4 patients malaise appeared to
worsen with repeated dosing of CT-2584 HMS, suggesting a
cumulative effect. 
Hypersensitivity reactions 
CT-2584 HMS is formulated in Cremophor®EL, other agents
formulated in this diluent can cause occasional hypersensitivity
reactions (HSR). Routine hypersensitivity prophylaxis was not
employed. 3 patients experienced HSR. One patient developed
widespread urticaria, moderate bronchospasm, lip oedema, chest
and back pain shortly after commencing day 1, cycle 2 infusion
at a dose of 65 mg/m2. This responded quickly to intravenous
hydrocortisone and chlorpheniramine. After 1 hour a cautious
rechallenge of CT-2584 HMS following premedication with
dexamethasone, chlorpheniramine and ranitidine was undertaken,
but resulted in a grade 2 HSR and further treatment was aban-
doned. A further patient, treated at 585 mg/m2, developed facial
flushing and backache two minutes into commencing day 1 of
cycle 2 of CT-2584 HMS. Treatment with hydrocortisone and
chlorpheniramine resolved the symptoms and the infusion was
recommenced without further problems. Another patient treated at
a dose level of 585 mg/m2 developed facial flushing, malaise,
backache and vomiting 5.5 h into the day 1, cycle 2 infusion. The
infusion was discontinued, the flushing and backache resolved
within 1 hour. The malaise improved over the following 3 days. 
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Table 2 CT-2584 HMS related toxicity by dose level 
Anorexia (grade) Nausea (grade) Vomiting (grade) 
0 1 2 3 4 0 1 2 34 01234  
65 2 1 2 1 2 1
130 5 1 4 1 1 5 1
215 2 1 1 2 2 1
325 1 2 2 1 2 1
455 5 1 2 3 1 4 2
520 4 2 1 1 3 1 2 3 1
585 2 1 1 1 1 2 1 
Proteinuria (grade) Haematuria (grade) Malaise (grade) 
0 1 2 3 4 0 1 2 34 01234  
65 2 1 3 1 1 1
130 5 1 5 1 3 3
215 2 1 2 1 1 1 1
325 3 3 1 1 1
455 3 2 1 3 3 1 1 4
520 2 3 1 4 1 1 2 3 1
585 1 1 1 1 2 1 1 1
Arrhythmia (grade) Hypotension (grade) Cardiac ischaemia (grade) 
0 1 2 3 4 0 1 2 34 01234  
65 3 3 3
130 6 6 6
215 3 3 3
325 3 3 3
4 5 5 51 41 1 5  1
520 6 5 1 6
585 2 1 3 3
Dose
mg/m2
Dose
mg/m2
Dose
mg/m2Other toxicity 
Headaches and dizziness related to CT-2548 HMS occurred in
30% and 27% of patients respectively. 
Catheter-related sepsis was seen in 7 patients, and one patient
developed a subclavian vein thrombosis. 
A possible reaction with alcohol consumption was noted. Two
patients reported flushing of the face and upper torso and malaise
(± vomiting and headache) when consuming alcohol within 3 days
of the last infusion of CT-2584 HMS. 
Pharmacokinetics 
Full pharmacokinetic data were obtained in 14 patients and day
2 pharmacokinetic data were obtained in 3 additional patients
(Tables 3 and 4). Cmax and AUC increased with increasing doses
except for the 215 mg/m2 dose group (which had only 1 patient in
the analysis). Increases in CT-2584 HMS plasma concentrations
appeared proportional to the dose and were similar on day 1
(Figure 1) and day 5 (Figure 2). After administration on day 1,
plasma elimination half-life ranged from 5.4 to 9.6 h (mean 7.3,
CV 19%) and was dose independent. Mean clearance values
ranged from 66 to 78 l h–1 on day 1 and from 46 to 78 l h–1 on day
5. Mean volume of distribution values ranged from 607 to 1006 l
on day 1 and from 466 to 822 l on day 5, exceeding the volume of
total body water in humans, thus indicating that CT2585 HMS was
extensively distributed in tissues. The CT-2584 HMS concentra-
tions associated with slow release from peripheral tissues were
low relative to total 24-hour exposure, and do not indicate a need
for dose adjustment during 5 days’ treatment with up to 520 mg/m2
CT-2584 HMS. 
Responses 
One partial response was seen in a male patient with pleural
mesothelioma, Butchart stage I, treated at 65 mg/m2 × 5 days for 6
cycles. Pleural thickening and an associated pleural effusion were
visible on baseline CT scanning. After 2 cycles of CT-2584 HMS,
the effusion had decreased in volume and the pleural thickening
had improved by approximately 40%. After 4 cycles of CT-2584
HMS a 65% improvement was seen which was maintained after 6
1604 SL Cheeseman et al
British Journal of Cancer (2000) 83(12), 1599–1606 © 2000 Cancer Research Campaign
Table 4 Pharmacokinetic results for CT-2584 HMS, cycle 1, day 5 
Dose (mg/m2)C max (µ g/ml) AUC (tf) (µ g h/ml) AUC (I) (µ g/h/ml) T1/2 (h) Vd (L) Cl (L/h) 
65 N analysed 1 1 1 1 1 1 
Value 0.248 1.722 1.956 6.9 652.8 66.0 
130 N analysed 6 6 6 6 6 6 
Mean (SD) 1.170 (1.47) 6.960 (6.08) 7.852 (6.42)  8.7 (4.32) 563.5 (474.95) 46.1 (31.87) 
CV% 126 87 82 49 84 69 
215 N analysed 1 1 1 1 1 1 
Value 0.531 5.466 6.429 6.6 465.6 48.8 
N analysed 2 2 2 2 2 2 
325 Mean (SD) 0.781 (0.14) 6.788 (1.41) 7.665 (1.19) 7.0 (0.34) 724.5 (106.76) 72.3 (14.14) 
CV% 18 21 15 5 15 20 
N analysed 3 3 3 3 3 3 
455 Mean (SD) 1.460 (0.23) 13.218 (3.24)  16.136 (3.69) 10.2 (2.19) 821.7 (353.36) 54.3 (12.55) 
CV% 15 25 23 21 43 23 
520 N analysed 1 1 1 1 1 1 
Mean (SD) 1.360 11.469 13.037 6.8 769.8  78.5 
Table 3 Pharmacokinetic results for CT-2584 HMS, cycle 1, day 1 
Dose (mg/m2)C max (µ g ml–1) AUC (tf) (µ g/h ml–1) AUC (I) (µ g h ml–1)T 1/2(h) Vd (L) Cl (L h–1) 
65 N analysed 1 1 1 1 1 1 
Value 0.138 0.822 n/v n/v n/v n/v 
N analysed 6 6 6 6 6 6 
130 Mean (SD) 0.671 (0.60) 4.747 (3.70) 5.211 (3.86) 7.3 (1.35) 683.5 (415.77) 65.8 (41.87) 
CV% 90 78 74 18 61 64 
215 N analysed 1 1 1 1 1 1 
Value 0.487 3.884 4.279 5.7 606.9 73.4 
N analysed 2 2 2 2 2 2 
325 Mean (SD) 0.792 (0.06) 6.643 (1.63) 7.507 (1.95) 9.1 (0.58) 1005.6 (362.34) 75.7 (22.70) 
CV% 8 24 26 6 36 30 
N analysed 4 4 4 4 4 4 
455 Mean (SD) 1.333 (0.24) 10.344 (3.00) 11.805 (3.51) 7.1 (0.81) 809.6 (325.93) 78.1 (2984) 
CV% 18 29 30 11 40 37 
N analysed 3 3 3 3 3 3 
520 Mean (SD) 1.563 (0.56) 12.664 (4.92) 14.015 (5.37) 6.7 (1.87) 803.9 (539.99) 76.6 (35.5) 
CV% 36 39 38 28 73 46 cycles. The response was confirmed by CT scan and continued for
8 months. 5 further patients had stable disease for ≥ 12 weeks. 
DISCUSSION 
Phosphatidic acid (PA) is a bioactive phospholipid which has been
implicated in a wide variety of cellular events, including cellular
proliferation and differentiation. CT-2584 HMS has been shown to
modulate PA metabolism in tumour cells and to exhibit select-
ive cytotoxicity to tumour cells in vitro. In vitro data suggested
increased cytotoxic effect with prolonged drug exposure.
Antitumour activity has been demonstrated in murine models and
in human tumour xenograft models, for these reasons, CT-2584
HMS was deemed suitable for further development as a cancer
therapy with a novel mechanism of action. Some PA isoforms have
been found to be pro-inflammatory; PA inhibitors have been inves-
tigated as anti-inflammatory agents and also agents to promote
bone marrow recovery after chemotherapy (Singer et al, 1994). 
This Phase I trial was designed to examine the safety and toler-
ability of this drug in humans. Dose levels of 65, 130, 215, 325,
455, 520 and 585 mg/m2 × 5 days were studied. 
Preclinical studies suggested that CT-2584 HMS may cause
anorexia, lethargy and intravascular haemolysis. No significant
haematological toxicity was seen. The similarities in chemical
structure between CT-2584 HMS and methylxanthines suggested
that CT-2584 HMS may cause cardiovascular side effects and this
was observed in 3 patients. Two patients treated at 455 mg/m2 × 5
days developed cardiac side effects; one patient developed chest
pain and ECG changes in keeping with cardiac ischaemia and a
further patient became hypotensive and developed worsening
bundle branch block during the day 3 infusion. Both patients
discontinued treatment and had no further cardiovascular sequelae.
A third patient developed atrial fibrillation during an episode of
sepsis. Toxicities commonly seen with current cytotoxic drugs
namely alopecia, bone marrow suppression and mucositis were not
observed. As expected in this population of patients, grade 1 and 2
anaemia was common and multifactorial in origin. Antiemetics
were not given routinely, and when treatment-related nausea or
vomiting occurred it was easily controlled. Preclinical studies
suggested that CT-2584 HMS could cause intravascular haemo-
lysis. 10 patients (33%) developed transient haematuria and 2
patients had transient increases in serum bilirubin with no clinical
sequelae. 
CT-2584 HMS is formulated in Cremophor®EL and 3 patients
experienced HSRs, in 2 patients this led to study withdrawal.
Patients were not routinely given prophylactic dexamethasone
prior to CT-2584 HMS infusion. The use of dexamethasone may
have decreased the incidence of HSR and resultant study drug
withdrawal. 
Malaise appeared to be dose related and was seen in the
majority of patients. In 4 patients the symptoms worsened as the
treatment progressed, suggesting a cumulative effect, although this
was not borne out in pharmacological studies. Treatment limiting
toxicity was malaise ± nausea ± headache. 
One patient died due to disease progression less than 30 days
after receiving CT-2584 HMS. No drug-related deaths or irre-
versible toxicities were noted. 
Preclinical toxicology cell line studies suggested CT-2584 HMS
was lethal to 50% of cells at concentrations of 6.14 µ M and inhib-
ited growth in 50% of cells at 1.68 µ m. Pharmacokinetic analysis
from patients treated up to 520 mg/m2 showed peak plasma
concentrations were achieved towards the end of the day 1 infu-
sion and increased between the patient cohorts with dose
given. Peak plasma concentrations ranged from approximately
0.2 µ g ml–1 (65 mg/m2) to 1.5 µ g ml–1 (520 mg/m2). Although these
figures are below LC50 and GI50 toxicity figures quoted from NCI
toxicity studies, a patient treated at 65 mg/m2 responded to this
dose level. Cell toxicity studies carried out in the Drug
Development Laboratories, Paterson Institute in Manchester
suggest that the GI50 is in the region of 0.2–0.8 µ g ml–1, well within
the plasma levels achieved with this treatment schedule. 
It was the intention of CTI to analyse patient serum samples for
changes in fatty acids. Unfortunately samples were damaged in
transit and were not suitable for assays on arrival. In-house PA
analysis for the final 2 cohorts of patients has confirmed a fall in
PA expression throughout the 5-day treatment schedule of CT-
2584 HMS. 
26 patients were evaluable for response. One patient, a 60-year-
old male with a malignant pleural mesothelioma, achieved a
partial response after 4 cycles of therapy which lasted for 8
months. Unfortunately, PA expression was not assessed during his
treatment, and therefore clinical therapeutic efficiency cannot be
directly compared to PA expression in this case. No other objective
responses were seen. 5 patients had stable disease for at least 12
weeks during CT-2584 HMS administration. 
CONCLUSION 
CT-2584 HMS was generally well tolerated at doses up 520 mg/m2
when administered as a 6-hour infusion via a central venous
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Figure 1. Mean CT-2584 HMS plasma concentration profiles by dose
(mg/m2) – Day 1 
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Figure 2. Mean CT-2584 HMS plasma concentration profiles by dose
(mg/m2) – Day 5catheter in a daily × 5 days schedule every 3 weeks. Two patients
developed drug-related adverse cardiac events at 455 mg/m2, but
no further cardiac side effects were seen at higher dose levels. At
doses of 520 mg/m2 and 585 mg/m2, the severity of malaise
increased. The treatment limiting toxicity was malaise, sometimes
accompanied by nausea and headache. It is possible that premed-
ication with steroids may reduce these side effects. It would be of
interest to study this during the proposed Phase II trials. A dose
level of 500 mg/m2 has been proposed for Phase II testing. 
A parallel trial was undertaken in the USA, with CT-2584 HMS
given as a 6-hour infusion for 3 consecutive days every 3 weeks.
Results from the USA and this UK study suggest that CT-2584
HMS may be active in sarcoma and hormone-resistant prostate
cancer.
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